Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 3
2(40.0%)
5Total
Phase 2(3)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06972264Phase 3Active Not Recruiting

Safety and Efficacy of VDPHL01 in Males With AGA

Role: lead

NCT07146022Phase 3Recruiting

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Role: lead

NCT06724614Phase 2Active Not Recruiting

Efficacy and Safety of VDPHL01 in Males With AGA

Role: lead

NCT06527365Phase 2Active Not Recruiting

Safety and Efficacy of VDPHL01 in Males and Females With AGA

Role: lead

NCT05799157Phase 2Completed

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Role: lead

All 5 trials loaded